United Therapeutics Corporation

NasdaqGS:UTHR 株式レポート

時価総額:US$16.6b

United Therapeutics 過去の業績

過去 基準チェック /36

United Therapeuticsは、平均年間30.7%の収益成長を遂げていますが、 Biotechs業界の収益は、年間 成長しています。収益は、平均年間19.3% 13.7%収益成長率で 成長しています。 United Therapeuticsの自己資本利益率は18.2%であり、純利益率は40.3%です。

主要情報

30.7%

収益成長率

29.6%

EPS成長率

Biotechs 業界の成長17.0%
収益成長率13.7%
株主資本利益率18.2%
ネット・マージン40.3%
前回の決算情報30 Sep 2024

最近の業績更新

Recent updates

United Therapeutics: One To Believe In Despite Competitive Threats

Nov 14

Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?

Oct 18
Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?

Benign Growth For United Therapeutics Corporation (NASDAQ:UTHR) Underpins Its Share Price

Sep 27
Benign Growth For United Therapeutics Corporation (NASDAQ:UTHR) Underpins Its Share Price

United Therapeutics: Economics Support Compounding Ability

Aug 20

With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case

Jul 26
With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case

United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet

Jul 04
United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet

United Therapeutics Corporation's (NASDAQ:UTHR) Business And Shares Still Trailing The Market

Jun 13
United Therapeutics Corporation's (NASDAQ:UTHR) Business And Shares Still Trailing The Market

United Therapeutics: Exciting Company With A Big Problem

Jun 02

We Ran A Stock Scan For Earnings Growth And United Therapeutics (NASDAQ:UTHR) Passed With Ease

Apr 05
We Ran A Stock Scan For Earnings Growth And United Therapeutics (NASDAQ:UTHR) Passed With Ease

United Therapeutics: Neutral Stance On Tyvaso's Patent Challenges And Future Growth Prospects

Mar 20

Is United Therapeutics (NASDAQ:UTHR) A Risky Investment?

Mar 15
Is United Therapeutics (NASDAQ:UTHR) A Risky Investment?

Investors Aren't Entirely Convinced By United Therapeutics Corporation's (NASDAQ:UTHR) Earnings

Jan 02
Investors Aren't Entirely Convinced By United Therapeutics Corporation's (NASDAQ:UTHR) Earnings

United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly

Dec 08
United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly

Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today

Nov 16
Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today

United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet

Sep 04
United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet

Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today

Aug 07
Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today

United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly

May 22
United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly

Does United Therapeutics (NASDAQ:UTHR) Deserve A Spot On Your Watchlist?

Apr 25
Does United Therapeutics (NASDAQ:UTHR) Deserve A Spot On Your Watchlist?

We Think United Therapeutics (NASDAQ:UTHR) Can Manage Its Debt With Ease

Feb 06
We Think United Therapeutics (NASDAQ:UTHR) Can Manage Its Debt With Ease

With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case

Jan 16
With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case

Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?

Oct 20
Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?

United Therapeutics: Ability To Expand Tyvaso To Large IPF Market

Aug 24

Do United Therapeutics' (NASDAQ:UTHR) Earnings Warrant Your Attention?

Aug 04
Do United Therapeutics' (NASDAQ:UTHR) Earnings Warrant Your Attention?

収支内訳

United Therapeutics の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。


収益と収入の歴史

NasdaqGS:UTHR 収益、費用、利益 ( )USD Millions
日付収益収益G+A経費研究開発費
30 Sep 242,7561,111607499
30 Jun 242,6171,069581480
31 Mar 242,4981,051533429
31 Dec 232,328985476408
30 Sep 232,204900499351
30 Jun 232,111872470332
31 Mar 231,981728481337
31 Dec 221,936727473323
30 Sep 221,860707448312
30 Jun 221,789631458324
31 Mar 221,768687429304
31 Dec 211,686476466410
30 Sep 211,655462499450
30 Jun 211,591471451440
31 Mar 211,506405444456
31 Dec 201,483515421358
30 Sep 201,410469364345
30 Jun 201,431430402362
31 Mar 201,443528336350
31 Dec 191,449-1043351,174
30 Sep 191,519-923131,199
30 Jun 191,530-1183241,214
31 Mar 191,601-1503671,220
31 Dec 181,628589269358
30 Sep 181,711543348333
30 Jun 181,744713285287
31 Mar 181,744484270264
31 Dec 171,725418333265
30 Sep 171,670509311218
30 Jun 171,632395363209
31 Mar 171,600657368184
31 Dec 161,599714319148
30 Sep 161,595708326157
30 Jun 161,5731,011209120
31 Mar 161,507904246135
31 Dec 151,466652453245
30 Sep 151,407663385241
30 Jun 151,351173604350
31 Mar 151,327186562340
31 Dec 141,289340381243
30 Sep 141,231194458293
30 Jun 141,203282350246
31 Mar 141,161250353261
31 Dec 131,117175394299

質の高い収益: UTHRは 高品質の収益 を持っています。

利益率の向上: UTHRの現在の純利益率 (40.3%)は、昨年(40.8%)よりも低くなっています。


フリー・キャッシュフローと収益の比較


過去の収益成長分析

収益動向: UTHR過去 5 年間で収益を上げており、収益は年間30.7%増加しています。

成長の加速: UTHRの過去 1 年間の収益成長率 ( 23.5% ) は、5 年間の平均 ( 年間30.7%を下回っています。

収益対業界: UTHRの過去 1 年間の収益成長率 ( 23.5% ) はBiotechs業界16.6%を上回りました。


株主資本利益率

高いROE: UTHRの 自己資本利益率 ( 18.2% ) は 低い とみなされます。


総資産利益率


使用総資本利益率


過去の好業績企業の発掘